Head and neck paragangliomas Paragangliomas and pheochromocytomas are rare, mostly benign neuroendocrine tumors, which are embryologically derived from neural crest cells of the autonomic nervous system. Paragangliomas are essentially the extra-adrenal counterparts of pheochromocytomas. As such this family of tumors can be subdivided into head and neck paragangliomas, pheochromocytomas and thoracic and abdominal extra-adrenal paragangliomas. Ten out of fifteen genes that contribute to the development of paragangliomas are more susceptible to the development of head and neck paragangliomas when mutated. Gene expression profiling revealed that pheochromocytomas and paragangliomas can be classified into two main clusters (C1 and C2) based on transcriptomes. These groups were defined according to their mutational status and as such strongly associated with specific tumorigenic pathways. The influence of the main genetic drivers on the somatic molecular phenotype was shown by DNA methylation and miRNA profiling. Certain subunits of succinate dehydrogenase (SDHx), von Hippel-Lindau (VHL) and transmembrane protein 127 (TMEM127) still have the highest impact on development of head and neck paragangliomas. The link between RAS proteins and the formation of pheochromocytoma and paragangliomas is clear due to the effect of receptor tyrosine-protein kinase (RET) and neurofibromatosis type 1 (NF1) in RAS signaling and recent discovery of the role of HRAS. The functions of MYC-associated factor X (MAX) and prolyl hydroxylase 2 (PHD2) mutations in the contribution to the pathogenesis of paragangliomas still remain unclear. Ongoing studies give us insight into the incidence of germline and somatic mutations, thus offering guidelines to early detection. Furthermore, these also show the risk of mistakenly assuming sporadic cases in the absence of definitive family history in head and neck paragangliomas.

Department of Biology and Medical Genetics 1st Faculty of Medicine and General University Hospital Charles University Prague Czech Republic

Department of Ear Nose and Throat and Maxillofacial Surgery 3rd Faculty of Medicine and Military University Hospital Charles University Prague Czech Republic

Department of Endocrinology and Metabolism 1st Faculty of Medicine and and General University Hospital Charles University Prague Czech Republic

Department of Otorhinolaryngology 3rd Faculty of Medicine and Kralovske Vinohrady University Hospital Charles University Prague Czech Republic

Department of Paediatric Haematology and Oncology 2nd Faculty of Medicine and University Hospital Motol Charles University Prague Czech Republic

Section on Medical Neuroendocrinology Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda United States

Zobrazit více v PubMed

CORSSMIT EP, ROMIJN JA. Clinical management of paragangliomas. Eur J Endocrinol 2014; 171 (6): R231–R243. PubMed

SAVARGAONKAR P & WASSERMAN PG. Paragangliomas: classification, pathology, and differential diagnosis. Otolaryngologic clinics of North America 2001; 34(5): 845–62, v–vi. PubMed

BOEDEKER CC. Paragangliomas and paraganglioma syndromes. Laryngorhinootologie 2011;90 suppl 1:S56–82. Doc03. PubMed

SOBOL SM, DAILEY JC. Familial multiple cervical paragangliomas: report of a kindred and review of the literature. Otolaryngol Head Neck Surg 1990; 102(4):382–90 PubMed

SAJID MS, HAMILTON G, BAKER DM, JOINT VASCULAR RESEARCH GROUP. A multicenter review of carotid body tumour management. Eur J Vasc Endovasc Surg 2007; 34(2): 127–30. PubMed

NAIK SM, SHENOY AM, NANJUNDAPPA, HALKUD R, CHAVAN P et al. Paragangliomas of the Carotid Body: Current Management Protocols and Review of Literature. Indian Journal of Surgical Oncology. 2013;4(3):305–312. doi:10.1007/s13193-013-0249-4.2013 PubMed DOI PMC

BOEDEKER C, HENSEN E, NEUMANN H, MALE W, VAN NEDERVEEN FH et al. Genetics of hereditary head and neck paragangliomas. Head Neck. 2014;36(6):907–916. 10.1002/hed.23436. PubMed DOI

JACKSON CG, GLASSCOCK ME, HARRIS PF. Glomus tumours: Diagnosis, classification and management of large lesions. Otolaryngol. 1982;08:401–406. PubMed

FISCH U, MATTOX D. Microsurgery of the Skull Base. New York: Thieme; 1988

BILLER HF, LAWSON W, SOM P, ROSENFELD R. Glomus vagale tumors. Ann Otol Rhinol Laryngol 1989;98(1 Pt 1):21–26 PubMed

WATSON DJ. Nasal paraganglioma. J Laryngol Otol. 1988;102:526–9 PubMed

LANGERMAN A, ATHAVALE SM, RANGARAJAN SV, SINARD RJ, NETTERVILLE JM. Natural History of Cervical Paragangliomas: outcomes of Observation of 43 Patients1993–2010. Arch Otolaryngol Head Neck Surg. 2012;138(4):341–345. doi:10.1001/archoto.2012.37 PubMed DOI

BARNES L Paraganglioma of the larynx. A critical review of the literature. ORL J Otorhinolaryngol Relat Spec. 1991;53(4):220–34 PubMed

VON DOBSCHUETZ E, LEIJON H, SCHALIN-JÄNTTI C, SCHIAVI F, et al. A registry-based study of thyroid paraganglioma: Histological and genetic characteristics. Endocrine-Related Cancer. 2015; 22(2): 191–204. DOI: 10.1530/ERC-14-0558 PubMed DOI

RINALDO A, MYSSIOREK D, DEVANEY KO, FERLITO A. Which paragangliomas of the head and neck have a higher rate of malignancy? Oral Oncol. 2004;40:458–60. PubMed

Martucci V, Pacak K. Pheochromocytoma and paraganglioma: Diagnosis, genetics, management, and treatment. Current Problems in Cancer. 2014;38(1):7–41. 10.1016/j.currproblcancer.2014.01.001 PubMed DOI PMC

Kirmani S, Young W. Hereditary Paraganglioma-Pheochromocytoma Syndromes. Ncbinlmnihgov. 2017. Available at: http://www.ncbi.nlm.nih.gov/books/NBK1548. Accessed December 19, 2017.

Piccini V, Rapizzi E, Bacca A, Di Trapani, Pulli R et al. Head and neck paragangliomas: genetic spectrum and clinical variability in 79 consecutive patients. Endocrine Related Cancer. 2012;19(2):149–155. 10.1530/erc-11-0369 PubMed DOI

Neumann H, Erlic Z, Boedeker C, Rybicki L, Robledo M. et al. Clinical Predictors for Germline Mutations in Head and Neck Paraganglioma Patients: Cost Reduction Strategy in Genetic Diagnostic Process as Fall-Out. Cancer Research 2009; 69(8), 3650–3656. 10.1158/0008-5472.can-08-4057 PubMed DOI

LATIF F, TORY K, GNARRA JR, YAO M, DUH FM, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science 1993; 260 (5112): 1317–20. PubMed

ENG C The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschprung’s disease. N Engl J Med 1996;335:943–51 PubMed

WHITE R AND O’CONNELL P. Identification and characterization of the gene for neurofibromatosis type 1. Current Opinion in Genetics & Development 1991; 115–19. doi:10.1016/0959-437X(91)80034-J. PubMed DOI

NEUMANN HP, BAUSCH B, MCWHINNEY SR, BENDER BU, GIMM O et al. Germ line mutations in non syndromic pheochromocytoma. New England Journal of Medicine 2002; 3461459–1466. doi:10.1056/NEJMoa020152. PubMed DOI

Baysal B, Ferrell R, Willett-Brozick J, Lawrence E, Myssiorek D, et al. Mutations in SDHD, a Mitochondrial Complex II Gene, in Hereditary Paraganglioma. Science. 2000;287(5454):848–851. 10.1126/science.287.5454.848. PubMed DOI

Astuti D, Latif F, Dallol A, Dahia P, Douglas F et al. (2001). Gene Mutations in the Succinate Dehydrogenase Subunit SDHB Cause Susceptibility to Familial Pheochromocytoma and to Familial Paraganglioma. The American Journal Of Human Genetics 2001; 69(1), 49–54. 10.1086/321282 PubMed DOI PMC

Niemann S & Müller U Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nature Genetics 2000; 26(3), 268–270. 10.1038/81551 PubMed DOI

Burnichon N, Brière J, Libé R, Vescovo L, Rivière J et al. SDHA is a tumor suppressor gene causing paraganglioma. Human Molecular Genetics 2010; 19(15), 3011–3020. 10.1093/hmg/ddq206 PubMed DOI PMC

Qin Y, Yao L, King EE, Buddavarapu K, Lenci RE et al. Germline mutations in TMEM127 confer susceptibility to pheochromocytoma. Nat Genet 2010; 42:229–233. 10.1038/ng.533 PubMed DOI PMC

Comino-Mendez I, Gracia-Aznarez FJ, Schiavi F, Landa I, Leandro-García LJ et al. Exome sequencing identifies MAX mutations as a cause of hereditary pheochromocytoma. Nat Genet. 2011; 43:663–667. 10.1038/ng.861 PubMed DOI

Castro-Vega L, Letouzé E, Burnichon N, Buffet A, Disderot PH et al. Multi-omics analysis defines core genomic alterations in pheochromocytomas and paragangliomas. Nature Communications. 2015;6:6044 10.1038/ncomms7044 PubMed DOI PMC

Gimenez-Roqueplo A, Dahia P, Robledo M. An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes. Hormone and Metabolic Research. 2012;44(05):328–333. 10.1055/s-0031-1301302. PubMed DOI

SCHLISIO S, KENCHAPPA RS, VREDEVELD LC, GEORGE RE, STEWART R et al. The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. Genes Dev. 2008;22(7):884–93. 10.1101/gad.1648608 PubMed DOI PMC

Ladroue C, Carcenac R, Leporrier M, Gad S, Le Hello C, et al. PHD2 mutation and congenital erythrocytosis with paraganglioma. N Engl JMed. 2008; 359:2685–92. 10.1056/NEJMoa0806277 PubMed DOI

GAAL J, BURNICHON N, KORPERSHOEK E, RONCELIN I, BERTHERAT J et al. Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. J Clin Endocrinol Metab. 2010;95:1274–1278. PubMed

Zhuang Z, Yang C, Lorenzo F, Merino M, Fojo T et al. Somatic HIF2AGain-of-Function Mutations in Paraganglioma with Polycythemia. New England Journal of Medicine. 2012;367(10):922–930. 10.1056/nejmoa1205119 PubMed DOI PMC

OUDIJK L, DE KRIJGER RR, RAPA I, BEUSCHLEIN F, DE CUBAS AA et al. H-RAS Mutations Are Restricted to Sporadic Pheochromocytomas Lacking Specific Clinical or Pathological Features: Data From a Multi-Institutional Series. J Clin Endocrinol Metab. 2014; 99(7): E1376–E1380. 10.1210/jc.2013-3879 PubMed DOI

de Cubas A, Leandro-Garcia L, Schiavi F, Mancikova V, Comino-Méndez I et al. Integrative analysis of miRNA and mRNA expression profiles in pheochromocytoma and paraganglioma identifies genotype-specific markers and potentially regulated pathways. Endocrine Related Cancer. 2013;20(4):477–493. 10.1530/erc-12-0183. PubMed DOI

Letouzé E, Martinelli C, Loriot C, Burnichon N, Abermil N et al. SDH Mutations Establish a Hypermethylator Phenotype in Paraganglioma. Cancer Cell. 2013;23(6):739–752. 10.1016/j.ccr.2013.04.018. PubMed DOI

de Cubas A, Korpershoek E, Inglada-Perez L, Letouzé E, Currás-Freixes M et al. DNA Methylation Profiling in Pheochromocytoma and Paraganglioma Reveals Diagnostic and Prognostic Markers. Clinical Cancer Research. 2015;21(13):3020–3030. 10.1158/1078-0432.ccr-14-2804. PubMed DOI

Burnichon N, Buffet A, Gimenez-Roqueplo A. Pheochromocytoma and paraganglioma: molecular testing and personalized medicine. Current Opinion in Oncology. 2016;28(1):5–10. 10.1097/cco.0000000000000249 PubMed DOI

Crona J, Delgado, Verdugo A, Maharjan R, Stalberg P, Granberg D et al. Somatic Mutations inH-RASin Sporadic Pheochromocytoma and Paraganglioma Identified by Exome Sequencing. The Journal of Clinical Endocrinology & Metabolism. 2013;98(7):E1266–E1271. 10.1210/jc.2012-4257 PubMed DOI

EISENHOFER G, Huynh T, Pacak K, Brouwers F, Walther M et al. Distinct gene expression profiles in norepinephrine- and epinephrine-producing hereditary and sporadic pheochromocytomas: activation of hypoxia-driven angiogenic pathways in von Hippel-Lindau syndrome. Endocrine Related Cancer. 2004;11(4):897–911. 10.1677/erc.1.00838 PubMed DOI

Dahia P, Ross K, Wright M, Hayashida CY, Santagata S et al. A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas. PLoS Genetics. 2005;1(1):e8 10.1371/journal.pgen.0010008 PubMed DOI PMC

López-Jiménez E, Gómez-López G, Leandro-García L, Munoz I, Schiavi F et al. Research Resource: Transcriptional Profiling Reveals Different Pseudohypoxic Signatures in SDHB and VHL-Related Pheochromocytomas. Molecular Endocrinology. 2010;24(12):2382–2391. 10.1210/me.2010-0256 PubMed DOI PMC

Burnichon N, Vescovo L, Amar L, Libe R, de Reynies A et al. Integrative genomic analysis reveals somatic mutations in pheochromocytoma and paraganglioma. Human Molecular Genetics. 2011;20(20):3974–3985. 10.1093/hmg/ddr324 PubMed DOI

Bayley J, Kunst H, Cascon A, Sampietro ML, Gaal J et al. SDHAF2 mutations in familial and sporadic paraganglioma and phaeochromocytoma. The Lancet Oncology. 2010;11(4):366–372. 10.1016/s1470-2045(10)70007-3 PubMed DOI

FAVIER J, BRIÈRE JJ, BURNICHON N, RIVIÈRE J, VESCOVO L, et al. The Warburg Effect Is Genetically Determined in Inherited Pheochromocytomas. PLOS ONE 2009; 4(9): e7094. PubMed PMC

Pasini B, Stratakis C. SDH mutations in tumorigenesis and inherited endocrine tumors: lesson from the phaeochromocytoma-paraganglioma syndromes. Journal Of Internal Medicine 2009; 266(1), 19–42. 10.1111/j.1365-2796.2009.02111.x PubMed DOI PMC

Burnichon N, Rohmer V, Amar L, Herman P, Leboulleux S. et al. The Succinate Dehydrogenase Genetic Testing in a Large Prospective Series of Patients with Paragangliomas. The Journal Of Clinical Endocrinology & Metabolism 2009; 94(8), 2817–2827. 10.1210/jc.2008-2504 PubMed DOI

SCHIAVI F, DEMATTÈ S, CECCHINI ME, TASCHIN E, BOBISSE S, DEL PIANO A et al. The endemic paraganglioma syndrome type 1: Origin, spread, and clinical expression. Journal of Clinical Endocrinology and Metabolism. 2012; 97(4). 10.1210/jc.2011-2597 PubMed DOI

Benn D, Gimenez-Roqueplo A, Reilly J, Bertherat J, Burgess J et al. Clinical Presentation and Penetrance of Pheochromocytoma/Paraganglioma Syndromes, The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):827–836. 10.1210/jc.2005-1862. PubMed DOI

van Duinen N, Corssmit E, de Jong W, Brookman D, Kema I et al. Plasma levels of free metanephrines and 3-methoxytyramine indicate a higher number of biochemically active HNPGL than 24-h urinary excretion rates of catecholamines and metabolites. European Journal of Endocrinology. 2013;169(3):377–382. 10.1530/eje-13-0529. PubMed DOI

VAN SCHOTHORST EM, JANSEN JC, GROOTERS E, PRINS DE, WIERSINGA JJ et al. Founder effect at PGL1 in hereditary head and neck paraganglioma families from the Netherlands. American Journal of Human Genetics. 1998;63(2):468–473 PubMed PMC

VAN DER MEY AG, MAASWINKEL-MOOY PD, CORNELISSE CJ, SCHMIDT PH, VAN DE KAMP JJ. Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet. 1989; 2(8675):1291–4; PubMed

PIGNY P, VINCENT A, CARDOT BAUTERS C, BERTRAND M, DE MONTPREVILLE VT et al. Paraganglioma after maternal transmission of a succinate dehydrogenase gene mutation. J Clin Endocrinol Metab. 2008; 93(5):1609–15; PubMed

Hensen E & Bayley J. Recent advances in the genetics of SDH-related paraganglioma and pheochromocytoma. Familial Cancer 2011; 10(2), 355–363. 10.1007/s10689-010-9402-1 PubMed DOI PMC

NEUMANN HP, PAWLU C, PECZKOWSKA M, BAUSCH B, MCWHINNEY SR, et al. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA. 2004;292:943–51 PubMed

HENSEN EF, JANSEN JC, SIEMERS MD, OOSTERWIJK JC, VRIENDS AH et al. The Dutch founder mutation SDHD.D92Y shows a reduced penetrance for the development of paragangliomas in a large multigenerational family. Eur J Hum Genet. 2009;18(1):62–6. PubMed PMC

VAN HULSTEIJN LT, DEKKERS OM, HES FJ, SMIT JW, CORSSMIT EP. Risk of malignant paraganglioma in SDHB-mutation and SDHD-mutation carriers: a systematic review and meta-analysis. Journal of Medical Genetics 2012;49:768–776 PubMed

Vicha A, Musil Z, & Pacak K, Genetics of pheochromocytoma and paraganglioma syndromes. Current Opinion In Endocrinology & Diabetes And Obesity 2013; 20(3), 186–191. 10.1097/med.0b013e32835fcc45 PubMed DOI PMC

Niemann S, Muller U, Engelhardt D & Lohse P. Autosomal dominant malignant and catecholamine-producing paraganglioma caused by a splice donor site mutation in SDHC. Hum Genet 2003; 113(1), 92–4. 10.1158/1078-0432.CCR-10-0420 PubMed DOI

Baysal B, Willett Brozick J, Filho P, Lawrence E, Myers E et al. An Alu-Mediated partial SDHC deletion causes familial and sporadic paraganglioma. Journal Of Medical Genetics 2004; 41(9), 703–709. 10.1136/jmg.2004.019224 PubMed DOI PMC

Schiavi F, Boedeker C, Bausch B, Peçzkowska M, Gomez C. et al. Predictors and Prevalence of Paraganglioma Syndrome Associated With Mutations of the SDHC Gene. JAMA 2005; 294(16), 2057–63. 10.1001/jama.294.16.2057 PubMed DOI

Neumann H, EnG C. The Approach to the Patient with Paraganglioma. The Journal Of Clinical Endocrinology & Metabolism 2009; 94(8), 2677–2683. 10.1210/jc.2009-0496 PubMed DOI PMC

PROYE C, VIX M, GOROPOULOS A, KERLO P, LECOMTE-HOUCKE M. High incidence of malignant pheochromocytoma in a surgical unit: 26 cases out of 100 patients operated from 1971 to 1991. J Endocrinol Invest. 1992;15:651–63. PubMed

Ricketts C, Forman J, Rattenberry E, Bradshaw N, Lalloo F et al. Tutor risks and genotype-phenotype-proteotype analysis in 358 patients with germline mutations in SDHB and SDHD. Human Mutation 2010; 31(1), 41–51. 10.1002/humu.21136 PubMed DOI

KLEIN RD, JIN L, RUMILLA K, YOUNG WF, LLOYD RV. Germline SDHB mutations are common in patients with apparently sporadic sympathetic paragangliomas. Diagn Mol Pathol. 2008;17: 94–100. PubMed

AMAR L, BAUDIN E, BURNICHON N, PEYRARD S, SILVERA S et al. Succinate dehydrogenase B gene mutations predict survival in subjects with malignant pheochromocytomas or paragangliomas. J Clin Endocrinol Metab 2007;92:3822–28 PubMed

GIMENEZ-ROQUEPLO A, FAVIER J, RUSTIN P, RIEUBLAND C, CRESPIN M et al. Mutations in the SDHB gene are associated with extra-adrenal and/or malignant phaeochromocytomas. Cancer research 2003; 63 (17): 5615–21. PubMed

Hao H, Khalimonchuk O, Schraders M, Dephoure N, Bayley J. et al. SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma. Science 2009; 325(5944), 1139–1142. 10.1126/science.1175689 PubMed DOI PMC

VAN BAARS F, VAN DEN BROEK P, CREMERS C, & VELDMAN J. FAMILIAL NON-CHROMAFFINIC PARAGANGLIOMAS (GLOMUS S). The Laryngoscope 1981; 91(6), 988–996. 10.1288/00005537-198106000-00019 PubMed DOI

Kunst H, Rutten M, de Monnink J, Hoefsloot L, Timmers H. et al. SDHAF2 (PGL2-SDH5) and Hereditary Head and Neck Paraganglioma. Clinical Cancer Research 2011; 17(2), 247–254. 10.1158/1078-0432.ccr-10-0420\ PubMed DOI

OFFERGELD C, Brase C, Yaremchuk S, MADER I, Rischke H et al. Head and neck paragangliomas: clinical and molecular genetic classification. Clinics (Sao Paulo) 2012; 67(SUPPL 1), 19–28. 10.6061/clinics/2012(Sup01)05 PubMed DOI PMC

Karasek D, Shah U, Frysak Z, Stratakis C, & Pacak K. An update on the genetics of pheochromocytoma. Journal Of Human Hypertension 2012; 27(3), 141–147. 10.1038/jhh.2012.20 PubMed DOI PMC

Boedeker C, Erlic Z, Richard S, Kontny U, Gimenez-Roqueplo A. et al. Head and Neck Paragangliomas in Von Hippel-Lindau Disease and Multiple Endocrine Neoplasia Type 2. The Journal Of Clinical Endocrinology & Metabolism 2009;, 94(6), 1938–1944. 10.1210/jc.2009-0354 PubMed DOI PMC

Pacak K, Jochmanova I, Prodanov T, Yang C, Merino MJ et al. New Syndrome of Paraganglioma and Somatostatinoma Associated With Polycythemia. J Clin Oncol. 2013. May 1; 31(13): 1690–1698. 10.1200/JCO.2012.47.1912 PubMed DOI PMC

Lorenzo FR, Yang C, Ng Tang Fui M, Vankayalapati H, Zhuang Z et al. A novel EPAS1/HIF2A germline mutation in a congenital polycythemia with paraganglioma. J Mol Med (Berl). 2013. April; 91(4):507–12. 10.1007/s00109-012-0967 PubMed DOI PMC

Wallace MR, Marchuk DA, Andersen LB, Letcher R, Odeh HM et al. Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. Science. 1990; 249:181–186. PubMed

Burnichon N, Buffet A, Parfait B, Letouze E, Laurendeau I et al. Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. Hum Mol Genet. 2012; 21:5397–5405. 10.1093/hmg/dds374 PubMed DOI

DeAngelis LM, Kelleher MB, Post KD, Fetell MR. Multiple paragangliomas in neurofibromatosis: a new neuroendocrine neoplasia. Neurology 1987;37:129–133. PubMed

Bausch B, Borozdin W, Neumann HP; European-American Pheochromocytoma Study Group. Clinical and genetic characteristics of patients with neurofibromatosis type 1 and pheochromocytoma.N Engl J Med. 2006. June 22;354(25):2729–31. 10.1056/NEJMc066006 PubMed DOI

Abermil N, Guillaud-Bataille M, Burnichon N, Venisse A, Manivet P et al. TMEM127 screening in a large cohort of patients with pheochromocytoma and/or paraganglioma. J Clin Endocrinol Metab. 2012; 97:E805–E809. 10.1210/jc.2011-3360 PubMed DOI

Burnichon N, Cascon A, Schiavi F, Morales NP, Comino-Mendez I et al. MAX mutations cause hereditary and sporadic pheochromocytoma and paraganglioma. Clin Cancer Res. 2012; 18:2828–2837. 10.1158/1078-0432.CCR-12-0160 PubMed DOI

Ivan HT, Haberberger T, Gervasi DC, Michelson KS, Gunzler V et al. Biochemical purification and pharmacological inhibition of a mammalian prolyl hydroxylase acting on hypoxia-inducible factor. Proceedings of the National Academy of Sciences of the United States of America. 2002; 99:13459–64. 10.1073/pnas.192342099 PubMed DOI PMC

Adari H, Lowy DR, Willumsen BM, Der CJ, McCornick F. Guanosine triphosphatase activatingprotein (GAP) interacts with the p21 ras effector binding domain. Science. 1988;240:518–21. 10.1126/science.2833817 PubMed DOI

King KS AND Pacak K. In Familial Pheochromocytomas and Paragangliomas. Mol Cell Endocrinol. 2014;386(0): 92–100. 10.1016/j.mce.2013.07.032. PubMed DOI PMC

Sridhara SK, Yener M, Hanna E, Rich T, Jimenez C et al. Genetic Testing in Head and Neck Paraganglioma: Who, What, and Why? J Neurol Surg B 2013;74:236–240. 10.1055/s-0033-1342924 PubMed DOI PMC

Fakhry N, Niccoli-Sire P, Barlier-Seti A, Giorgi R, Giovanni A et al. Cervical paragangliomas: is SDH genetic analysis systematically required? Eur Arch Otorhinolaryngol 2008;265(5):557–563. 10.1007/s00405-007-0517-4 PubMed DOI

Zhu WD, Wang ZY, Chai YC, Wang XW, Chen DY et al. Germline mutations and genotype-phenotype associations in head and neck paraganglioma patients with negative family history in China. Eur J Med Genet 2015; 58:433–438. 10.1016/j.ejmg.2015.05.008 PubMed DOI

Heesterman BL, Bayley JP, Tops CM, Hes FJ, van Brussel BT et al. High prevalence of occult paragangliomas in asymptomatic carriers of SDHD and SDHB gene mutations. Eur J Hum Genet 2013; 21:469–470. 10.1038/ejhg.2012.203 PubMed DOI PMC

Welander J, Larsso C, Backdahl M, Hareni N, Sivler T et al. Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. Hum Mol Genet. 2012;21:5406–5416. PubMed

Chen H, Zhu W, Li X, Xue L, Wang Z et al. Genetic and epigenetic patterns in patients with the head- and-neck paragangliomas associate with differential clinical characteristics. J Cancer Res Clin Oncol 2017; 143:953–960. 10.1007/s00432-017-2355-0 PubMed DOI PMC

ZHIKRIVETSKAYA SO, SNEZHKINA AV, ZARETSKY AR, ALEKSEEV BY, POKROVSKY AV et al. Molecular markers of paragangliomas/pheochromocytomas. Oncotarget. 2017; 8(15):25756–25782. PubMed PMC

Editorial: Management of neuroendocrine tumors of the head and neck

Paragangliomas and syringomyelia in Tetralogy of Fallot-A case report and literature review

High incidence of occult familial SDHD cases amongst Czech patients with head and neck paragangliomas

Head and Neck Paragangliomas in the Czech Republic: Management at the Otorhinolaryngology Department

Genetic Variants in Patients with Multiple Head and Neck Paragangliomas: Dilemma in Management